Vumerity vs. Ocrevus

• Are Vumerity and Ocrevus the Same Thing?
• What Are Possible Side Effects of Vumerity?
• What Are Possible Side Effects of Ocrevus?
• What Is Vumerity?
• What Is Ocrevus?
• What Drugs Interact with Vumerity?
• What Drugs Interact with Ocrevus?
• How Should Vumerity Be Taken?
• How Should Ocrevus Be Taken?

Vumerity (diroximel fumarate) and Ocrevus (ocrelizumab) are used to treat relapsing forms of multiple sclerosis (MS).

Ocrevus is also used to treat primary progressive forms of multiple sclerosis.

Vumerity and Ocrevus belong to different drug classes. Vumerity is an immunomodulator and Ocrevus is a CD20-directed cytolytic antibody.

Side effects of Vumerity that are different from Ocrevus include flushing, abdominal pain, diarrhea, nausea, vomiting, itching, rash, albumin in the urine, redness, and indigestion/heartburn.

Side effects of Ocrevus that are different from Vumerity include upper and lower respiratory tract infections, infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate), skin infections, depression, back pain, and pain in the extremities.

Vumerity may interact with dimethyl fumarate.

Ocrevus may interact with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids.

Common side effects of Vumerity include:

• flushing,
• abdominal pain,
• diarrhea,
• nausea,
• vomiting,
• itching,
• rash,
• albumin in the urine,
• redness, and
• indigestion/heartburn

Common side effects of Ocrevus include:

• upper respiratory tract infections,
• infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate),
• skin infections,
• lower respiratory tract infections,
• depression,
• back pain, and
• pain in the extremities.

Vumerity (diroximel fumarate) is an immunomodulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Ocrevus (ocrelizumab) injection is aCD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.

Vumerity may interact with other medicines such as:

• dimethyl fumarate

Tell your doctor all medications and supplements you use.

Hepatitis B virus screening is required before the first dose of Ocrevus. Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine prior to each infusion. The starting dose of Ocrevus is 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses of Ocrevus are 600 mg intravenous infusion every 6 months.

The starting dose of Vumerity is 231 mg twice a day, orally, for 7 days. The maintenance dose of Vumerity after 7 days is 462 mg (administered as two 231 mg capsules) twice a day, orally.

The recommended dosage of Ocrevus is 12 mg/day administered by intravenous infusion for 2 treatment courses: First Treatment Course: 12 mg/day on 5 consecutive days (60 mg total dose; Second Treatment Course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the first treatment course.